Mark Glaum
Allergy & Immunology · Tampa, FLNPI 1073598744
Payments from drug & device makers
Across 461 payments — averaging $730.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$91K
- Shire North American Group Inc$77K
- Takeda Pharmaceuticals U.S.A., Inc.$74K
- Biocryst US Sales Co., LLC$65K
- Ionis Pharmaceuticals, Inc.$18K
- Biocryst Pharmaceuticals, Inc.$3K
- plus $7K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 110 | $91,281 |
| Shire North American Group Inc | 118 | $76,880 |
| Takeda Pharmaceuticals U.S.A., Inc. | 69 | $74,220 |
| Biocryst US Sales Co., LLC | 49 | $65,274 |
| Ionis Pharmaceuticals, Inc. | 21 | $18,232 |
| Biocryst Pharmaceuticals, Inc. | 3 | $3,430 |
| Genentech USA, Inc. | 3 | $1,767 |
| Alk-abello, Inc | 2 | $1,609 |
| Blueprint Medicines Corporation | 1 | $1,485 |
| Novartis | 11 | $481 |
| Regeneron Healthcare Solutions, Inc. | 9 | $451 |
| GSK | 16 | $304 |
| Sanofi-aventis U.S. LLC | 2 | $191 |
| Pfizer | 10 | $188 |
| AstraZeneca | 9 | $159 |
| Sanofi | 5 | $148 |
| Amgen | 3 | $68 |
| Pharming Healthcare, Inc. | 3 | $65 |
| Covis Pharma GmbH | 3 | $59 |
| LEO Pharma Inc. | 2 | $50 |
| Optinose US, Inc. | 3 | $45 |
| Kaleo, Inc. | 3 | $43 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $29 |
| Grifols USA, LLC | 1 | $21 |
| Galderma Laboratories, L.p. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| AbbVie | 1 | $18 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$336,551 in reported general payments places this provider in the 90th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Tampa
- Thomas CasaleTampa$1.7M
- Dennis LedfordTampa$1.4M
- Seong ChoTampa$969K
- Amber PepperTampa$583K
- Juan Carlos CardetTampa$468K
- Richard LockeyTampa$227K
- Farnaz TabatabaianTampa$76K
- Ammar HatabTampa$14K
- Jaime LandmanAventura$3.9M
- Ileana RodicioMiami$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.